Last Updated : January 26, 2023
Details
FilesGeneric Name:
selpercatinib
Project Status:
Complete
Therapeutic Area:
Thyroid cancer
Manufacturer:
Eli Lilly Canada Inc.
Brand Name:
Retevmo
Project Line:
Reimbursement Review
Project Number:
PC0264-000
Tumour Type:
Head and Neck
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Retevmo is indicated as monotherapy for the treatment of: RET-mutant medullary thyroid cancer in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Retevmo is indicated as monotherapy for the treatment of: RET-mutant medullary thyroid cancer in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | September 14, 2021 |
|---|---|
| Call for patient/clinician input closed | November 05, 2021 |
| Clarification: - Patient input submission received from GroupCanCertainty, Canadian Cancer Societyâs patient panels and networks, and Thyroid Cancer Canada patient networks | |
| Submission received | October 29, 2021 |
| Submission accepted | November 17, 2021 |
| Review initiated | November 18, 2021 |
| Draft CADTH review report(s) provided to sponsor for comment | February 17, 2022 |
| Deadline for sponsors comments | March 01, 2022 |
| CADTH review report(s) and responses to comments provided to sponsor | April 01, 2022 |
| Expert committee meeting (initial) | April 13, 2022 |
| Draft recommendation issued to sponsor | April 27, 2022 |
| Draft recommendation posted for stakeholder feedback | May 05, 2022 |
| End of feedback period | May 19, 2022 |
| Clarification: - Reconsideration: major revisions requested by sponsor - Target EXPERT COMMITTEE reconsideration meeting date to be determined | |
| Expert committee meeting | September 14, 2022 |
| Final recommendation issued to sponsor and drug plans | September 26, 2022 |
| Final recommendation posted | October 13, 2022 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | October 11, 2022 |
| CADTH review report(s) posted | December 22, 2022 |
Files
Last Updated : January 26, 2023